HMECC Ukraine Signs Memorandum of Understanding with Yangtze River Pharmaceutical Group
Kyiv, Ukraine — August 8, 2025
A major milestone in strengthening healthcare cooperation between China and Ukraine was reached today as HMECC Ukraine officially signed a Memorandum of Understanding (MoU) with one of China’s leading pharmaceutical companies — Yangtze River Pharmaceutical Group (YRPG).
During an online meeting involving senior representatives from both sides, key partnership objectives were discussed, including:
- Facilitating the introduction of Chinese pharmaceutical products into the Ukrainian market,
- Organizing pilot shipments to both public and private medical institutions,
- Supporting registration and certification of YRPG products in Ukraine through HMECC channels.
Ivan Khomych, President of HMECC Ukraine, stated:
“We believe this collaboration with YRPG will give Ukrainian patients access to high-quality, innovative, and affordable medical solutions, and serve as a model of Sino-Ukrainian cooperation in the pharmaceutical sector.”
YRPG representatives expressed their readiness to send a preliminary product catalog and begin coordination of the regulatory process in Ukraine with the support of HMECC.
